Prothena Corp Public (PRTA) Cash from Investing Activities (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Cash from Investing Activities of -$10000.0 for Q3 2025, down 11.11% year-over-year from -$11250.0 in Q3 2024, and up 88.37% quarter-over-quarter from -$86000.0 in Q2 2025.
Powered by 
Analysis
Prothena Corp Public (PRTA) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Prothena Corp Public's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$10000.0 for Q3 2025.
- In Q3 2025, Cash from Investing Activities fell 11.11% year-over-year to -$10000.0; the TTM figure through Mar 2026 stood at -$96000.0 (up 59.49% YoY), while the FY2025 annual figure was -$138000.0, up 53.69% from the prior year.
- Cash from Investing Activities for Q3 2025 stood at -$10000.0, up from -$86000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was -$9000.0 in Q3 2024, with the low at -$1.5 million in Q4 2023.
- The 5-year median for Cash from Investing Activities is -$116500.0 (2022), against an average of -$236000.0.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities plunged 901.32% in 2023, then jumped 97.96% in 2024.
- Prothena Corp Public's Cash from Investing Activities stood at -$319000.0 in 2021, then soared by 52.66% to -$151000.0 in 2022, then slumped by 901.32% to -$1.5 million in 2023, then surged by 97.16% to -$43000.0 in 2024, then soared by 76.74% to -$10000.0 in 2025.
- Business Quant data shows PRTA's Cash from Investing Activities at -$10000.0 in Q3 2025, -$86000.0 in Q2 2025, and -$42000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Prothena Corp Public | 507.63 Mn | 219.43 Mn | - | -652,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -652,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -86,000.00 |
| Mar 31, 2025 | -42,000.00 |
| Dec 31, 2024 | -43,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2024 | -143,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | -1.51 Mn |
| Sep 30, 2023 | -442,000.00 |
| Jun 30, 2023 | -771,000.00 |
| Mar 31, 2023 | -48,000.00 |
| Dec 31, 2022 | -151,000.00 |
| Sep 30, 2022 | -130,000.00 |
| Jun 30, 2022 | -161,000.00 |
| Mar 31, 2022 | -22,000.00 |
| Dec 31, 2021 | -319,000.00 |
| Sep 30, 2021 | -208,000.00 |
| Mar 31, 2021 | -48,000.00 |
| Dec 31, 2020 | -51,000.00 |